Procter & Gamble Health Limited (PGHL.BO)
INR 5104.95
(-0.72%)
INR 5104.95
(-0.72%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.99 Billion INR | -47.63% |
| 2022 | 5.71 Billion INR | 7.25% |
| 2021 | 5.33 Billion INR | 24.27% |
| 2020 | 4.29 Billion INR | 109.42% |
| 2019 | 2.04 Billion INR | -49.45% |
| 2018 | 4.05 Billion INR | 27.41% |
| 2017 | 3.18 Billion INR | -26.09% |
| 2016 | 4.3 Billion INR | 11.53% |
| 2015 | 3.85 Billion INR | -3.47% |
| 2014 | 3.99 Billion INR | 15.77% |
| 2013 | 3.45 Billion INR | 26.08% |
| 2012 | 2.73 Billion INR | 32.29% |
| 2011 | 2.07 Billion INR | 0.81% |
| 2010 | 2.05 Billion INR | 20.46% |
| 2009 | 1.7 Billion INR | 23.83% |
| 2008 | 1.37 Billion INR | 55.67% |
| 2007 | 884.7 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 651 Million INR | -39.63% |
| 2023 FY | 2.99 Billion INR | -47.63% |
| 2023 Q4 | 1.07 Billion INR | 71.92% |
| 2023 Q3 | 627.2 Million INR | -49.76% |
| 2023 Q2 | 1.24 Billion INR | -7.93% |
| 2023 Q1 | 1.35 Billion INR | -19.56% |
| 2022 Q4 | 1.68 Billion INR | 12.98% |
| 2022 FY | 5.71 Billion INR | 7.25% |
| 2022 Q3 | 1.49 Billion INR | 18.05% |
| 2022 Q2 | 1.26 Billion INR | -1.03% |
| 2022 Q1 | 1.27 Billion INR | 28.7% |
| 2021 Q1 | 1.21 Billion INR | 12.42% |
| 2021 Q3 | 1.24 Billion INR | -5.09% |
| 2021 Q4 | 992.4 Million INR | -20.55% |
| 2021 Q2 | 1.31 Billion INR | 8.12% |
| 2021 FY | 5.33 Billion INR | 24.27% |
| 2020 Q3 | 1.29 Billion INR | 35.06% |
| 2020 Q2 | 957.4 Million INR | -2.57% |
| 2020 FY | 4.29 Billion INR | 109.42% |
| 2020 Q1 | 982.7 Million INR | -6.17% |
| 2020 Q4 | 1.08 Billion INR | -16.26% |
| 2019 FY | 2.04 Billion INR | -49.45% |
| 2019 Q3 | 934.21 Million INR | 0.0% |
| 2019 Q1 | 1.01 Billion INR | -16.94% |
| 2019 Q4 | 1.04 Billion INR | 12.1% |
| 2018 Q2 | 1.27 Billion INR | 24.89% |
| 2018 FY | 4.05 Billion INR | 27.41% |
| 2018 Q4 | 1.22 Billion INR | 16.12% |
| 2018 Q3 | 1.05 Billion INR | -17.36% |
| 2018 Q1 | 1.01 Billion INR | -4.07% |
| 2017 FY | 3.18 Billion INR | -26.09% |
| 2017 Q4 | 1.06 Billion INR | -10.18% |
| 2017 Q3 | 1.18 Billion INR | 5.11% |
| 2017 Q2 | 1.12 Billion INR | 17.68% |
| 2017 Q1 | 955.58 Million INR | -0.27% |
| 2016 Q1 | 1.17 Billion INR | 1.13% |
| 2016 FY | 4.3 Billion INR | 11.53% |
| 2016 Q4 | 958.12 Million INR | -21.68% |
| 2016 Q3 | 1.22 Billion INR | -5.4% |
| 2016 Q2 | 1.29 Billion INR | 10.12% |
| 2015 Q4 | 1.16 Billion INR | -3.2% |
| 2015 Q1 | 1.11 Billion INR | 12.61% |
| 2015 Q2 | 1.06 Billion INR | -4.66% |
| 2015 Q3 | 1.19 Billion INR | 12.51% |
| 2015 FY | 3.85 Billion INR | -3.47% |
| 2014 Q1 | 962.04 Million INR | 9.47% |
| 2014 Q4 | 993.03 Million INR | 4.19% |
| 2014 Q3 | 953.09 Million INR | -17.61% |
| 2014 FY | 3.99 Billion INR | 15.77% |
| 2014 Q2 | 1.15 Billion INR | 20.25% |
| 2013 Q2 | 848.64 Million INR | -3.58% |
| 2013 Q3 | 1 Billion INR | 17.94% |
| 2013 Q4 | 878.85 Million INR | -12.19% |
| 2013 FY | 3.45 Billion INR | 26.08% |
| 2013 Q1 | 880.12 Million INR | -2.77% |
| 2012 Q1 | 650.86 Million INR | -7.76% |
| 2012 Q4 | 905.17 Million INR | 10.38% |
| 2012 Q3 | 820.05 Million INR | 209.67% |
| 2012 FY | 2.73 Billion INR | 32.29% |
| 2012 Q2 | 264.81 Million INR | -59.31% |
| 2011 Q3 | 616.53 Million INR | 81.08% |
| 2011 Q1 | 644.56 Million INR | 0.0% |
| 2011 FY | 2.07 Billion INR | 0.81% |
| 2011 Q4 | 705.61 Million INR | 14.45% |
| 2011 Q2 | 340.47 Million INR | -47.18% |
| 2010 FY | 2.05 Billion INR | 20.46% |
| 2009 FY | 1.7 Billion INR | 23.83% |
| 2008 FY | 1.37 Billion INR | 55.67% |
| 2007 FY | 884.7 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 81.125% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 92.366% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 74.268% |
| Granules India Limited | 7.18 Billion INR | 58.295% |
| Indoco Remedies Limited | 4.74 Billion INR | 36.923% |
| Achyut Healthcare Limited | 1.6 Million INR | -186065.32% |
| Ajanta Pharma Limited | 30.46 Billion INR | 90.167% |
| Alkem Laboratories Limited | 32.83 Billion INR | 90.877% |
| Alpa Laboratories Limited | 156.14 Million INR | -1818.321% |
| Brooks Laboratories Limited | 51.18 Million INR | -5752.677% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -15.19% |
| Bajaj HealthCare Limited | 985.34 Million INR | -203.995% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -111.059% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 96.876% |
| Eris Lifesciences Limited | 4.94 Billion INR | 39.4% |
| FDC Limited | 5.34 Billion INR | 43.996% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 95.567% |
| Gufic Biosciences Limited | 1.07 Billion INR | -177.941% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -41.014% |
| Ipca Laboratories Limited | 13.91 Billion INR | 78.473% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -287.298% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -6389.73% |
| Lasa Supergenerics Limited | 291.17 Million INR | -928.732% |
| Laurus Labs Limited | 3.01 Billion INR | 0.511% |
| Lupin Limited | 95.67 Billion INR | 96.869% |
| Mankind Pharma Limited | 23.15 Billion INR | 87.062% |
| Medicamen Biotech Limited | 335.16 Million INR | -793.704% |
| Medico Remedies Limited | 161.84 Million INR | -1750.795% |
| Megasoft Limited | 49.52 Million INR | -5947.892% |
| NATCO Pharma Limited | 10.05 Billion INR | 70.219% |
| Piramal Pharma Limited | 19.91 Billion INR | 84.958% |
| RPG Life Sciences Limited | 1.63 Billion INR | -83.149% |
| Sigachi Industries Limited | 579.88 Million INR | -416.549% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.057% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -113.532% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -217.848% |
| Unichem Laboratories Limited | 6.72 Billion INR | 55.464% |
| Wanbury Limited | 1.16 Billion INR | -158.018% |
| Windlas Biotech Limited | 1 Billion INR | -197.603% |
| ZIM Laboratories Limited | 1.01 Billion INR | -195.679% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 93.062% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 2.646% |
| Divi's Laboratories Limited | 14.17 Billion INR | 78.861% |
| Hester Biosciences Limited | 908.84 Million INR | -229.585% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -172.56% |
| Bal Pharma Limited | 389.89 Million INR | -668.268% |
| Strides Pharma Science Limited | 9.16 Billion INR | 67.307% |
| Venus Remedies Limited | 1.91 Billion INR | -56.313% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 2.57% |
| Nectar Lifesciences Limited | 625.55 Million INR | -378.843% |
| Shilpa Medicare Limited | 2.18 Billion INR | -37.367% |
| Aarti Drugs Limited | 1.16 Billion INR | -156.57% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -172.606% |
| Suven Life Sciences Limited | 109.75 Million INR | -2629.294% |
| Ind-Swift Limited | 946.56 Million INR | -216.449% |
| Valiant Laboratories Limited | 36.28 Million INR | -8154.292% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 64.413% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 34.594% |
| Themis Medicare Limited | 782.85 Million INR | -282.625% |
| Hikal Limited | 2.48 Billion INR | -20.474% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 86.017% |
| Sequent Scientific Limited | 2.9 Billion INR | -3.225% |
| Novartis India Limited | 470.1 Million INR | -537.184% |
| Wockhardt Limited | 6.4 Billion INR | 53.197% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 79.276% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -18379.06% |
| Neuland Laboratories Limited | 2.92 Billion INR | -2.241% |
| Morepen Laboratories Limited | 1.98 Billion INR | -50.716% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -626.286% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -343.01% |